title: The retrospective analysis of patients with uterine sarcomas: A single-center experience.
abstract: BACKGROUND
  Uterine sarcomas are rare, malignant, gynecological tumors and show diverse histopathological features. Therefore, there is no consensus on risk factors for poor outcome and optimal treatment. The aim of this retrospective analysis is to report the clinical outcome of patients with uterine sarcoma treated at a single center.
  
  
  METHODS
  The data was obtained regarding the patient's demographic characteristics, pathological results, treatments given, survival, and complications of all uterine sarcoma patients treated in a single center between the years 2000 and 2012. The 80.month overall survival. (OS) was determined with respect to prognostic factors including age, stage of disease, histopathological type, and adjuvant treatment.
  
  
  RESULTS
  A total of 57 case records are retrieved for this retrospective analysis. The mean age of the patients is 62.5 ± 11.2 years. International Federation of Gynecology and Obstetrics (FIGO) stage distribution is stage I: 29; stage II: 13; stage III: 9; stage IV: 6. Fifty-seven patients underwent surgery, 33 received postoperative radiotherapy (PORT), and 32 received chemotherapy. Median follow-up period was 25 months (range 2-85 months). The 80-month OS for the entire group of patients was 36.7%. The significant prognostic factors for survival are age under 50 years, stage of disease, and adjuvant chemotherapy.
  
  
  CONCLUSIONS
  Although limited by small sample size and retrospective nature, age under 50 years, stage of disease, and adjuvant chemotherapy are significant prognostic factors for survival for uterine sarcomas.
authors.forename: Mustafa Cosan
authors.initials: MC
authors.lastname: Terek
authors.affiliation: Department of Obstetrics and Gynecology, Ege University Medical School, Izmir, Turkey.
authors.forename: Levent
authors.initials: L
authors.lastname: Akman
authors.forename: Behiye Seda
authors.initials: BS
authors.lastname: Hursitoglu
authors.forename: Ulus Ali
authors.initials: UA
authors.lastname: Sanli
authors.forename: Zeynep
authors.initials: Z
authors.lastname: Ozsaran
authors.forename: Mustafa Agah
authors.initials: MA
authors.lastname: Tekindal
authors.forename: Yilmaz
authors.initials: Y
authors.lastname: Dikmen
authors.forename: Osman
authors.initials: O
authors.lastname: Zekioglu
authors.forename: Ahmet Aydin
authors.initials: AA
authors.lastname: Ozsaran
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007044:Hysterectomy; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D018714:Radiotherapy, Adjuvant; D012189:Retrospective Studies; D012509:Sarcoma / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D016896:Treatment Outcome; D014594:Uterine Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery